QID 352277

Date Published: 2021-05-13

QID 352277: Amazon Linux Security Update for exim: ALAS-2021-1497

Issue Overview:

Prior versions of Exim 4 have Improper Neutralization of Line Delimiters. Local users can alter the behavior of root processes because a recipient address can have a newline character. (CVE-2020-28015)

Prior versions of Exim 4 allowed Integer Overflow to Buffer Overflow in receive_add_recipient via an e-mail message with fifty million recipients. NOTE: remote exploitation may be difficult because of resource consumption. (CVE-2020-28017)

Prior versions of Exim 4 allowed Use After Free in smtp_reset in certain situations that may be common for builds with OpenSSL. (CVE-2020-28018)

Prior versions of Exim 4 have Improper Neutralization of Line Delimiters. An authenticated remote SMTP client can insert newline characters into a spool file (which indirectly leads to remote code execution as root) via AUTH= in a MAIL FROM command. (CVE-2020-28021)

Allows unauthorized disclosure of information; allows unauthorized modification; allows disruption of service.

CVSS V3 rated as Critical - 9.8 severity.

CVSS V2 rated as Critical - 9 severity.

Solution

Administrators are advised to apply the appropriate software updates.

Vendor References

ALAS-2021-1497 - alas.aws.amazon.com/ALAS-2021-1497.html

CVEs related to QID 352277

CVE-2020-28018 | CVE-2020-28015 | CVE-2020-28021 | CVE-2020-28017 |

Software Advisories

Advisory ID	Software	Component	Link
ALAS-2021-1497	Amazon Linux		alas.aws.amazon.com/ALAS-2021-1497.html

By selecting these links, you may be leaving CVEreport webspace. We have provided these links to other websites because they may have information that would be of interest to you. No inferences should be drawn on account of other sites being referenced, or not, from this page. There may be other websites that are more appropriate for your purpose. CVEreport does not necessarily endorse the views expressed, or concur with the facts presented on these sites. Further, CVEreport does not endorse any commercial products that may be mentioned on these sites. Please address comments about any linked pages to [email protected].